PARP inhibitor
AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy
Phil Taylor
AstraZeneca, BRCA, breast cancer, Merck & Co, Oncology, PARP inhibitor, regulatory approval, targeted oncology
0 Comment
After a Scottish aye, NICE says no to Lynparza for prostate cancer
Phil Taylor
AstraZeneca, HEOR, Lynparza, NICE, PARP inhibitor, Prostate cancer
0 Comment
PROpel study backs Lynparza combo in first-line prostate cancer
Phil Taylor
AstraZeneca, Lynparza, Merck & Co, Oncology, PARP inhibitor, Prostate cancer
0 Comment
ASCO21: Lynparza aces adjuvant breast cancer therapy trial
Phil Taylor
adjuvant, ASCO 2021, AstraZeneca, breast cancer, Lynparza, Merck & Co, Oncology, PARP inhibitor
0 Comment
NICE says no to AZ’s Lynparza for prostate cancer
Phil Taylor
AstraZeneca, HEOR, Lynparza, NHS, NICE, Oncology, PARP inhibitor, Prostate cancer, UK
0 Comment
Filing beckons as Lynparza hits the mark in adjuvant breast cancer
Phil Taylor
adjuvant, AstraZeneca, breast cancer, Lynparza, Oncology, PARP inhibitor
0 Comment
Triple Negative Breast Cancer Drug Development Digital Summit
jenna.warren@hansonwade.com
adc, immunotherapy, Oncology, PARP inhibitor, TNBC
0 Comment
Fast-track the Discovery & Development of TNBC
AZ, Merck add pancreatic cancer to Lynparza’s growing use list
Phil Taylor
AstraZeneca, Lynparza, Merck & Co, pancreatic cancer, PARP inhibitor
0 Comment